In the instance of Cases 4&5, predictive genetic testing for NBN and FANCD2 is currently not clinically indicated according to the guidelines due to their unknown associated risk and a lack of evidence regarding clinical management for BC and OVC (Table 2). The gene discussed is FANCD2; the disease is breast cancer.